-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Adhera Therapeutics, a clinical-stage biopharmaceutical company, announced today that it has begun production of MLR-1019 (armesocarb) for phase IIa clinical trials
.
Adhera also announced that a new patent for MLR-1019 has been issued in South Korea
Adhera is actively conducting a Phase IIa study, which aims to be a multi-center, double-blind, randomized, placebo-controlled clinical trial in Eastern Europe to evaluate the effectiveness and safety of MLR-1019 in the treatment of Parkinson's.
MLR-1019 is expected to solve sports and non-sports problems at the same time
.
MLR-1019 is expected to solve sports and non-sports problems at the same time
.
Adhera is actively conducting a Phase IIa study, which aims to be a multi-center, double-blind, randomized, placebo-controlled clinical trial in Eastern Europe to evaluate the effectiveness and safety of MLR-1019 in the treatment of Parkinson's.
Andrew Kucharchuk, CEO of Adhera Therapeutics, commented: "Product manufacturing is a milestone for us because we are one step closer to launching a milestone study for Parkinson's disease
.
"
Armesocarb is the active enantiomer of mesocarb.
Mesocarb is a medicine that has been on the market for 37 years in Europe and is used to treat various mental illnesses and central nervous system diseases
.
Through the treatment of more than 1 million patients and the work that has been published in more than 100 publications, mesocarb has been proven to be safe and well tolerated in a wide range of therapeutic doses
Adhera has received the MLR-1019 patent certificate (Korea Patent No.
10-2301073) issued by the Korean Intellectual Property Office
.
Currently MLR-1019 has obtained 12 patents (3 in the United States, 1 in the European Union, 1 in Australia, 1 in China, 1 in Eurasia, 1 in Israel, 1 in Mexico, 1 in South Africa, 1 in South Korea, 1 in Hong Kong) and 7 pending patents (1 each in the United States, Japan, Brazil, Canada, South Korea, New Zealand and Singapore)
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// leave a message here
